Why Myriad Genetics (MYGN) Stock Is Trading Up Today

Why Myriad Genetics (MYGN) Stock Is Trading Up Today

Adam Hejl

Wed, February 25, 2026 at 1:26 AM GMT+9 2 min read

In this article:

MYGN

+3.54%

What Happened?

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 4.9% in the morning session after the company reported better-than-expected fourth-quarter 2025 earnings that surpassed analyst forecasts for both revenue and profit.

The genetic testing company announced revenue of $209.8 million, slightly ahead of Wall Street’s projections. More impressively, Myriad posted an adjusted profit of $0.04 per share, a significant beat compared to the forecasted loss of $0.02 per share. Adding to the positive sentiment, the company’s adjusted EBITDA of $14.3 million more than doubled expectations, and its full-year EBITDA guidance of $43 million also came in ahead of consensus estimates. While quarterly revenue was flat year on year, the strong profitability and positive outlook were a welcome surprise for investors, who had already pushed the stock up 22% in the previous session.

After the initial pop the shares cooled down to $4.55, up 3.8% from previous close.

Is now the time to buy Myriad Genetics? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Myriad Genetics’s shares are extremely volatile and have had 43 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 1 day ago when the stock dropped 3.9% on the news that the Trump administration’s announcement of new global tariffs reignited trade policy uncertainty.

The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.

Myriad Genetics is down 26% since the beginning of the year, and at $4.55 per share, it is trading 67% below its 52-week high of $13.78 from February 2025. Investors who bought $1,000 worth of Myriad Genetics’s shares 5 years ago would now be looking at an investment worth $151.00.

While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report, it’s free.

Terms and Privacy Policy

Privacy Dashboard

More Info